2-(4-Chlorophenyl)-8-(piperidin-4-ylamino)imidazo[1,2-a]pyrazine-5-carboxamide | 1169426-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-Chlorophenyl)-8-(piperidin-4-ylamino)imidazo[1,2-a]pyrazine-5-carboxamide
• CAS: 1169426-33-8
• 化学式: C₁₈H₁₉ClN₆O
• 分子量: 370.841
• InChiKey: UIBANLKKSQACJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  97.3
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(4-Chlorophenyl)-8-(piperidin-4-ylamino)imidazo[1,2-a]pyrazine-5-carbonitrile 在 硫酸 作用下， 生成 2-(4-Chlorophenyl)-8-(piperidin-4-ylamino)imidazo[1,2-a]pyrazine-5-carboxamide
  参考文献：
  名称：

  Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors

  摘要：

  Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.

  DOI：

  10.1016/j.bmcl.2013.03.100

文献信息

• IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
  申请人：Ciavarri Jeffrey P.

  公开号：US20090175852A1

  公开（公告）日：2009-07-09

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
• [EN] IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES EN TANT QU'INHIBITEURS DE PROTÉINES KINASES
  申请人：SCHERING CORP

  公开号：WO2010088368A2

  公开（公告）日：2010-08-05

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
• Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors
  作者：Zhaoyang Meng、Jeffrey P. Ciavarri、Andrew McRiner、Yinyan Zhao、Lianyun Zhao、Panduranga Adulla Reddy、Xingmin Zhang、Thierry O. Fischmann、Charles Whitehurst、M. Arshad Siddiqui

  DOI：10.1016/j.bmcl.2013.03.100

  日期：2013.5

  Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.